AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BIOPHARMA CREDIT PLC

Notice of Dividend Amount Dec 7, 2017

4973_rns_2017-12-07_5ab1d75f-062b-4beb-b789-bc9165212890.html

Notice of Dividend Amount

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7423Y

BioPharma Credit PLC

07 December 2017

BIOPHARMA CREDIT PLC

("BIOPHARMA CREDIT" OR THE "COMPANY")

DIVIDEND DECLARATION

The Company is pleased to declare an interim dividend in respect of the financial period ending 30 September 2017 of $0.01 per ordinary share, payable on 31 January 2018 to ordinary shareholders on the register as at 15 December 2017. The dividend will be paid as 0.9938 cents per ordinary share as an interest payment and 0.0062 cents per ordinary share as an ordinary dividend. The dividend is in line with the Company's announced initial target yield of 4% per annum.

The Company has chosen to designate part of this interim dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest in respect of the interest distribution element of this dividend. This will result in a reduction in the corporation tax payable by the Company.

Link Company Matters Limited

Company Secretary

7 December 2017

Enquiries:

Buchanan

David Rydell/Mark Court/ Jamie Hooper/ Henry Wilson

+44 (0) 20 7466 5000

[email protected]

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27th March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS

The company news service from the London Stock Exchange

END

DIVTRBFTMBMMBLR

Talk to a Data Expert

Have a question? We'll get back to you promptly.